Last updated: February 14, 2026
Market Analysis and Price Projections for NDC 42291-0496
Overview
NDC 42291-0496 is Risdiplam (Evrysdi), developed by Roche. It is an oral medication for treating spinal muscular atrophy (SMA) in patients two months and older. Launched in 2020, it has gained regulatory approval in multiple markets, including the US, EU, and Japan.
Market Size and Demand
- SMA is a rare genetic neuromuscular disorder affecting approximately 1 in 10,000 live births.
- The global SMA treatment market was valued at around USD 1.5 billion in 2022.
- Risdiplam competes with existing therapies such as Biogen's Spinraza (nusinersen) and Novartis's Zolgensma (onasemnogene abeparvovec).
Competitive Landscape
- Spinraza remains the market leader, holding about 60% market share as of 2022.
- Zolgensma targets the gene therapy segment, positioned for infants and new diagnoses.
- Risdiplam, as an oral option, appeals due to ease of administration and broader patient accessibility, especially outside clinical settings.
Pricing and Reimbursement
- US list price as of 2023: approximately USD 340,000 annually per patient.
- European pricing varies by country, generally ranging from EUR 250,000 to EUR 400,000.
- In Japan, government reimbursement has set the price at about USD 250,000 per year.
Price Projections
- Short-term (next 1-2 years):
- US prices likely stabilize around USD 340,000 to USD 350,000.
- Europe may see slight reductions due to negotiations, with list prices around EUR 230,000- EUR 280,000.
- Medium-term (3-5 years):
- Entry of biosimilars or new formulations may pressure prices downward by 10-20%.
- Increased competitive pressure may also lead to discounts in both US and European markets.
- Long-term (beyond 5 years):
- As biosimilars or alternative therapies enter the market, prices could decline by 25-40%.
- Patent expiration in the US is expected around 2031, which could facilitate generic or biosimilar entry.
Market Dynamics Influencing Price
- The high cost of SMA therapies influences payer and insurer negotiations.
- Payor coverage expands as more insurers include Risdiplam based on its convenience.
- Use of real-world evidence may result in formulary adjustments.
- Development of generic versions post-patent expiration remains critical for price reductions.
Regulatory and Policy Impact
- Discount mandates or price caps in European markets could reduce prices.
- The US Inflation Reduction Act (2022) impacts drug pricing negotiations, potentially leading to value-based pricing models for Risdiplam.
Summary
Risdiplam’s market position is strengthened by its oral administration, but pricing remains aligned with its high-cost, specialized niche. Price pressure is expected to increase if biosimilars or alternative therapies gain regulatory approval and market penetration in the next five years.
Key Takeaways
- Risdiplam (NDC 42291-0496) is positioned in a high-cost, niche SMA market.
- The US list price remains around USD 340,000 annually, with European prices averaging EUR 250,000- EUR 400,000.
- Market projections suggest potential price declines of 10-40% within five years due to biosimilar entry and policy changes.
- Competitive dynamics and regulatory environments significantly influence future pricing strategies.
FAQs
1. How does Risdiplam's price compare to Spinraza and Zolgensma?
Risdiplam’s US list price (~USD 340,000/year) is comparable to Spinraza’s initial annual cost (~USD 125,000, with escalation) but typically higher than Zolgensma’s one-time therapy (~USD 2.1 million), which is designed for a single administration in infancy.
2. What factors could cause Risdiplam's price to decline?
Introduction of biosimilars, changes in reimbursement policies, increased competition, and patent expiration can exert downward pressure on prices.
3. How does market access influence Risdiplam pricing?
Positive reimbursement decisions and coverage from large payors stabilize prices; restrictive policies or formulary exclusions can reduce prices.
4. Are there pricing differences between markets?
Yes. While the US maintains higher list prices due to less centralized regulation, European and Japanese markets negotiate prices, often resulting in lower final prices.
5. When could biosimilars or generics enter the market for Risdiplam?
Patent expiration is projected around 2031 in the US, after which biosimilar or generic options could emerge, potentially reducing prices by 25-40%.
References
[1] EvaluatePharma, 2022. SMA Market Data.
[2] U.S. Food and Drug Administration. FDA Label for Evrysdi.
[3] European Medicines Agency. Marketing Authorization for Evrysdi.
[4] IQVIA, 2023. Global Price and Reimbursement Data.
[5] U.S. Inflation Reduction Act, 2022.
